0001144204-19-047664.txt : 20191008
0001144204-19-047664.hdr.sgml : 20191008
20191008160612
ACCESSION NUMBER: 0001144204-19-047664
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20191008
DATE AS OF CHANGE: 20191008
EFFECTIVENESS DATE: 20191008
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: EYEGATE PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001372514
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-350635
FILM NUMBER: 191142793
BUSINESS ADDRESS:
STREET 1: 271 WAVERLEY OAKS ROAD
STREET 2: SUITE 108
CITY: WALTHAM
STATE: MA
ZIP: 02452
BUSINESS PHONE: 781-788-9043
MAIL ADDRESS:
STREET 1: 271 WAVERLEY OAKS ROAD
STREET 2: SUITE 108
CITY: WALTHAM
STATE: MA
ZIP: 02452
D
1
primary_doc.xml
X0708
D
LIVE
0001372514
EYEGATE PHARMACEUTICALS INC
271 WAVERLEY OAKS ROAD
SUITE 108
WALTHAM
MA
MASSACHUSETTS
02452
781-788-9043
DELAWARE
None
None
Corporation
true
Stephen
From
271 Waverley Oaks Road, Suite 108
Waltham
MA
MASSACHUSETTS
02452
Executive Officer
Director
President and CEO
Sarah
Romano
271 Waverley Oaks Road, Suite 108
Waltham
MA
MASSACHUSETTS
02452
Executive Officer
CFO
Paul
Chaney
271 Waverley Oaks Road, Suite 108
Waltham
MA
MASSACHUSETTS
02452
Director
Praveen
Tyle
271 Waverley Oaks Road, Suite 108
Waltham
MA
MASSACHUSETTS
02452
Director
Morton
Goldberg
271 Waverley Oaks Road, Suite 108
Waltham
MA
MASSACHUSETTS
02452
Director
Peter
Greenleaf
271 Waverley Oaks Road, Suite 108
Waltham
MA
MASSACHUSETTS
02452
Director
Thomas
Hancock
271 Waverley Oaks Road, Suite 108
Waltham
MA
MASSACHUSETTS
02452
Director
Bernard
Malfroy-Camine
271 Waverley Oaks Road, Suite 108
Waltham
MA
MASSACHUSETTS
02452
Director
Steven
Boyd
271 Waverley Oaks Road, Suite 108
Waltham
MA
MASSACHUSETTS
02452
Director
Pharmaceuticals
Decline to Disclose
- 06b
false
2019-10-02
false
true
true
true
false
0
1875000
1875000
0
false
1
0
0
0
Some of the proceeds may be used for working capital and other general corporate purposes, which may include the payment of salaries and other fees to those listed in Item 3.
false
EYEGATE PHARMACEUTICALS INC
/s/ Stephen From
Stephen From
President and CEO
2019-10-08